drugset / Trial / NCT05181865
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced cancer.
Timeline
- Start
- 2022-01
- Primary completion
- 2022-01-18
- Completion
- 2022-01-18
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FL-301 | Unknown | 1 mg/kg | Intravenous |
| Subject | FL-301 | Unknown | 3 mg/kg | Intravenous |
| Subject | FL-301 | Unknown | 10 mg/kg | Intravenous |
| Subject | FL-301 | Unknown | 20 mg/kg | Intravenous |
| Subject | FL-301 | Unknown | 30 mg/kg | Intravenous |